



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

09/987,931 11/16/2001 Kevin Qun Fang 4821-439-999 7960

20582 7590 03/12/2007

JONES DAY
222 East 41st Street
New York, NY 10017-6702

EXAMINER

KIM, VICKIE Y

ART UNIT

PAPER NUMBER

1618

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
--	-----------	---------------

3 MONTHS

03/12/2007

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary

Application No.

09/987,931

Applicant(s)

KEVIN QUN FANG

Examiner

Vickie Kim

Art Unit

1618

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 127-132 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 127-132 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. ____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|--|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date <u>12/11/06</u> . | 6) <input type="checkbox"/> Other: ____ |

DETAILED ACTION

Status of Application

1. Acknowledgement is made of amendment filed 12/8/06. Upon entering the amendment, the claim 127 is amended.
2. The pending claims are 127-132 and presented for the examination.

Response to Arguments

In view of amendment filed 12/8/06, 112, 1st scope of enablement rejection is withdrawn. However, Applicant's arguments with respect to claims 127-132 are not persuasive and the rejection is maintained for the substantially same reason set forth in previous office action.

Claim Rejections - 35 USC § 112, 1st: withdrawn in view of amendment filed 12/8/06.

103 rejection

1. Applicant's argument is not persuasive. In response to applicant's argument that there is no suggestion to combine the references, the examiner recognizes that obviousness can only be established by combining or modifying the teachings of the prior art to produce the claimed invention where there is some teaching, suggestion, or motivation to do so found either in the references themselves or in the knowledge generally available to one of ordinary skill in the art. See *In re Fine*, 837 F.2d 1071, 5 USPQ2d 1596 (Fed. Cir. 1988) and *In re Jones*, 958 F.2d 347, 21 USPQ2d 1941 (Fed. Cir. 1992). In this case, state of art clearly recognizes substitution a drug with an active

Art Unit: 1618

metabolite is advantageous because the potency of active metabolite where the dose used in the therapy can be minimized and therefore, unwanted side effect can be reduced not only small dose used but also other avoidance of other inactive metabolite being in blood stream which also causes unwanted side effect. For example, in this case, Morgan clearly states in his patent that advantages of use of active metabolite (i.e. compound 1, S.S hydroxybupropion) and its in vivo anti-depressant activity through NA mechanisms(col. 8, lines 10-20). Table 1 also supports high potency of S.S hydroxybupropion's activity through NA pathway proven by low dose of formula I used. Therefore, the fact that applicant has recognized another advantage which would flow naturally from following the suggestion of the prior art cannot be the basis for patentability when the differences would otherwise be obvious. See *Ex parte Obiaya*, 227 USPQ 58, 60 (Bd. Pat. App. & Inter. 1985).

For the reasons above, the claims are maintained as rejected and same 103 rejection(previously issued) are repeated hereafter.

Claim Rejections - 35 USC § 103

3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

4. Claims 127-132 are rejected under 35 U.S.C. 103(a) as being unpatentable over Morgan (US6274579, 6391875, 2003/0064988) in view of Spier (1998, abstract only,

Art Unit: 1618

Use of bupropion with SRIs and venlafaxine) or Bodkin et al(1997, combining serotonin reuptake inhibitors and burpopion....).

Note: all these patents are children cases of US6274579 and disclosures therein are substantially same. Therefore, the examiner will use US'579 to represent all these cases.

The claims are drawn to a method of treating or preventing an affective disorders such as obesity(weight gain), or cocccain addiction, attention deficit hyperactivity disorder(ADHD) by administering a therapeutically or prophylactically effective amount of a bupropion metabolite such as (+)-(2S, 3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol and adjunctively effective amount of secondary active compound.

Morgan et al(US'579) teaches a compound (+)-(2S, 3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol and its composition used for treating depression, attention deficit hyperactivity disorder(ADHD), obesity or addiction to cocaine or nicotine containing product(e.g. tobacco), see abstract.

The critical elements required by the claims are well taught by the cited reference(s) except that they required secondary active compound such as SSRI or 5HT compound..

However, it would have been obvious to one of ordinary skill in the art at that time of the invention was made to add secondary active agent when Morgan(US'579) is taken in view of Spier's or Bodkin's reference because latter reference teaches the combination drug treatment wherein bupropion is main active agent combined with an

Art Unit: 1618

effective amount of secondary active agent(e.g. SSRIs) effectively used in the treatment of various affective disorders.

Spier(1998) or Bodkin et al(1997) teaches a combination drug of bupropion and SRI's in the treatment of depression, see abstract. It also teaches that the drug response is superior in combination drug therapy compared to monotherapy.

Since Morgan teaches that bupropion's anti-depressant activity is resulted from the active metabolite in vivo, i.e. (+)-(2S, 3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol(see col. 8, lines 15-20), one would have been motivated, with reasonable expectation of success, to add SSRI or 5HT compound as secondary active compound into antidepressant(i.e. (+)-(2S, 3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol) to treat affective disorders because the combination drug treatment improves efficacy by lowering side effects and achieve additive pharmacological effect because these agents are utilizing different underlying mechanisms as taught in Cary and Howard references. It is clearly suggested in later references that combination drug treatment could enhance drug efficacy and improve industrial applicability as well. Furthermore, combination drug therapy is standard drug regimen well known in the field of psychiatry medicine, see extrinsic supporting documents PTO-892, for instance, Zarate(2003, Combination treatment in bipolar disorder) or Post et al(1997, previously cited).

One would have been motivated to combine these references and make the modification because they are drawn to same technical fields (constituted with same ingredients and share common utilities, and pertinent to the problem which applicant concerns about. MPEP 2141.01(a).

Art Unit: 1618

5. Claims 127-132 are rejected under 35 U.S.C. 103(a) as being unpatentable over Howard et al(US6677678) or Cary (WO99/17803) in view of Morgan et al((US6274579).

The claims are drawn to a method of treating or preventing an affective disorders such as obesity(weight gain), or cocaine addiction, attention deficit hyperactivity disorder(ADHD) by administering a therapeutically or prophylactically effective amount of a bupropion metabolite such as (+)-(2S, 3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol and adjunctively effective amount of secondary active compound.

Firstly, Howard et al (US'678 hereinafter) teach SSRI(serotonin selective reuptake inhibitors) used in the treatment of affective disorders such as major depressive disorder. Furthermore, in the background section, US'736 teaches an advantages obtained from a combination drug treatment of SSRI and bupropion(see col. 1, lines 10-25) where synergism and reduction of side effects can be seen in combination of SSRIs and bupropion drug treatment.

Secondly, Cary(WO'803) also teaches a nicotine or other substance addiction treatment such as cocaine or alcohol addiction by applying a combination drug regimen where bupropion and nicotine receptor antagonists such as fluoxetine(SSRI), imipramine(5HT), mecamylamine are effectively used as active agent, col.4, lines 5-38.

The claims are differ in that they require bupropion's metabolite rather than bupropion itself.

Art Unit: 1618

As mentioned earlier,(supra), Morgan teaches that bupropion's anti-depressant activity is resulted from the active metabolite in vivo, i.e. (+)-(2S, 3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol(see col. 8, lines 15-20).

In light of Morgan(US6274579) teaching, one would have been motivated, with reasonable expectation of success, to substitute bupropion with its active metabolite (i.e. (+)-(2S, 3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol), and administer combination drug(i.e. SSRI or 5HT compound as secondary active compound into antidepressant(i.e. bupropion metabolite) to treat affective disorders because the metabolite is the active form where optimal drug dosage regimen can be used for determining most efficient drug treatment. Additionally combination drug treatment can be benefited by optimal dose used in the treatment because it could maximally lower side effects and furthermore, achieve additive or synergistic pharmacological effect because these agents are utilizing different underlying mechanisms as taught in Cary and Howard references.

All the critical elements required by the instant claims are well taught in the cited reference and thus, the claimed subject matter is not patentably distinct over the prior art of the record.

Double Patenting

6. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

Art Unit: 1618

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

7. Claims 127-132 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 13-15 and 58 – 78 of copending Application No. 09/987930 in view of Spier, Howard or Cary(see above in 103 rejection). both inventions are drawn to the similar invention where the scoped of the invention is overlapping substantially. For the same reason set forth in 103 rejection, the claimed subject matter shared overlapping scope(i.e. a treatment of affective disorders using (2S, 3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol) and the combination with secondary is clearly envisioned when secondary teaching is taken together.

This is a provisional obviousness-type double patenting rejection.

Conclusion

8. No claim is allowed.

9. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not

Art Unit: 1618

mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Vickie Kim whose telephone number is 571-272-0579. The examiner can normally be reached on Tuesday-Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Hartley be reached on 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

VICKIE KIM
PRIMARY EXAMINER

Vickie Kim
Primary Patent Examiner
March 5, 2007
Art unit 1618